Red Biotech develops algae-based drugs to combat immune deficiencies, particularly after traumatic brain injury. Utilizing marine sulfated polysaccharides, they aim to treat immuno-depression resulting from such injuries. Clinical tests on 82 patients showed positive results, highlighting the potential of these algae-derived molecules in curing immune diseases and infections, reinforcing Red Biotech's innovative approach in medical treatments.
